Susan Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, outcomes and health services researchers and others involved in health policy research across all of Merck, with the goal of providing health technology assessment agencies and those involved in formulary decisions with the best available information on the value our medicines provide.
Prior to joining Merck, Dr Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva, Inc. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics (including pricing) and global market access, both for the primary care business unit, and for emerging markets/established products business unit.
Dr Shiff has also led a risk management group and US HEOR group at Roche and spent four years at the U.S. Centers for Disease Control and Prevention (CDC). She received her PhD degree from UCLA, and an MBA degree from Cornell University.